Ultralinq has acquired Intelesens, a wearable device manufacturer spun out from Ulster University in 2001.

Scottish Investment Bank has supported a funding round for Causeway Therapeutics, a spinout from University of Glasgow that is working on treatments for tendon injuries and disorders.

Cambridge Enterprise has licensed key technology to Qkine, a spinout that is working on proteins to control stem cell growth.

Paul Ashley and Brendan Ludden will be responsible for life sciences and physical sciences, respectively.

Lundbeck has taken part in a $67m series C round for Amplyx Pharmaceuticals, which is developing treatments for life-threatening fungal infections.

UCB Pharma scored an exit after the bone disease therapy developer floated at the top of its range, having secured $92.5m in funding over the past two years.

Cardiovascular therapy developer Milestone Pharmaceuticals will use proceeds from the Novo-led round to advance its lead candidate to a phase 3 clinical trial.

Homology Medicines, a startup developing treatments for rare genetic diseases, has closed $83.5m in series B funding, welcoming Novartis as a new investor.